Compare Stocks → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CYCCNASDAQ:LPCNNASDAQ:MYOSOTCMKTS:NVLNFNASDAQ:SLRX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCCCyclacel Pharmaceuticals$2.07+5.6%$2.43$1.82▼$13.20$1.74M0.56156,869 shs46,092 shsLPCNLipocine$5.20+1.4%$4.04$2.31▼$5.95$27.66M1.0229,629 shs48,922 shsMYOSMYOS RENS Technology$1.37$3.35$0.74▼$3.85$16.70M1.081.68 million shs1 shsNVLNFNovelion Therapeutics$0.70-1.2%$0.70$0.51▼$1.00$13.77M2.15261,364 shs26,900 shsSLRXSalarius Pharmaceuticals$0.53+8.2%$0.59$0.43▼$2.68$2.28M1.04114,617 shs73,346 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCCCyclacel Pharmaceuticals+3.50%-5.91%-23.90%-22.47%-75.79%LPCNLipocine-0.19%+26.52%+34.72%+86.38%-7.64%MYOSMYOS RENS Technology0.00%-0.72%-5.52%-68.86%+427.53%NVLNFNovelion Therapeutics0.00%0.00%0.00%0.00%0.00%SLRXSalarius Pharmaceuticals+3.44%-9.66%-14.71%-17.41%-73.83%“The Stock Market’s Bull Run is Far from Over” -Barrons (Ad)Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYCCCyclacel Pharmaceuticals2.0606 of 5 stars3.35.00.00.02.10.00.6LPCNLipocine0.0492 of 5 stars0.02.00.00.03.00.00.0MYOSMYOS RENS TechnologyN/AN/AN/AN/AN/AN/AN/AN/ANVLNFNovelion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASLRXSalarius Pharmaceuticals1.1295 of 5 stars0.05.00.00.03.20.01.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYCCCyclacel Pharmaceuticals2.50Moderate Buy$21.00914.49% UpsideLPCNLipocineN/AN/AN/AN/AMYOSMYOS RENS TechnologyN/AN/AN/AN/ANVLNFNovelion TherapeuticsN/AN/AN/AN/ASLRXSalarius Pharmaceuticals2.00HoldN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYCCCyclacel Pharmaceuticals$420K4.14N/AN/A$0.72 per share2.88LPCNLipocine$500K55.33N/AN/A$3.83 per share1.36MYOSMYOS RENS Technology$1.03M16.22N/AN/A$0.13 per share10.54NVLNFNovelion Therapeutics$130.43M0.11N/AN/A($4.69) per share-0.15SLRXSalarius Pharmaceuticals$1.84M1.24N/AN/A$4.56 per share0.12Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYCCCyclacel Pharmaceuticals-$22.56M-$27.22N/AN/AN/AN/A-448.19%-151.29%5/9/2024 (Estimated)LPCNLipocine-$16.35M-$3.05N/AN/AN/AN/A-63.28%-58.27%5/9/2024 (Estimated)MYOSMYOS RENS Technology-$4.26MN/AN/A∞N/A-277.82%-166.68%-104.95%N/ANVLNFNovelion Therapeutics-$108.33MN/A0.00∞N/AN/AN/AN/AN/ASLRXSalarius Pharmaceuticals-$12.54M-$4.53N/AN/AN/AN/A-197.96%-135.23%5/9/2024 (Estimated)Latest MYOS, LPCN, SLRX, CYCC, and NVLNF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023LPCNLipocine-$0.53-$0.42+$0.11-$0.42N/A$0.22 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYCCCyclacel PharmaceuticalsN/AN/AN/AN/AN/ALPCNLipocineN/AN/AN/AN/AN/AMYOSMYOS RENS TechnologyN/AN/AN/AN/AN/ANVLNFNovelion TherapeuticsN/AN/AN/AN/AN/ASLRXSalarius PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYCCCyclacel PharmaceuticalsN/A0.910.91LPCNLipocineN/A8.698.69MYOSMYOS RENS Technology0.113.781.94NVLNFNovelion TherapeuticsN/AN/AN/ASLRXSalarius PharmaceuticalsN/A5.023.59OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYCCCyclacel Pharmaceuticals23.58%LPCNLipocine9.11%MYOSMYOS RENS Technology4.97%NVLNFNovelion Therapeutics48.64%SLRXSalarius Pharmaceuticals11.88%Insider OwnershipCompanyInsider OwnershipCYCCCyclacel Pharmaceuticals8.47%LPCNLipocine5.00%MYOSMYOS RENS Technology45.30%NVLNFNovelion Therapeutics3.60%SLRXSalarius Pharmaceuticals5.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCYCCCyclacel Pharmaceuticals2,018840,000772,000OptionableLPCNLipocine175.32 million5.05 millionNo DataMYOSMYOS RENS Technology1512.19 millionN/ANot OptionableNVLNFNovelion Therapeutics10919.62 millionN/ANot OptionableSLRXSalarius Pharmaceuticals124.31 million4.08 millionNot OptionableMYOS, LPCN, SLRX, CYCC, and NVLNF HeadlinesSourceHeadlineWall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Datamsn.com - March 27 at 1:54 AMWhy Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarketmsn.com - March 25 at 11:52 AMSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updatefinanznachrichten.de - March 23 at 8:07 AMSalarius: Q4 Earnings Snapshotsfgate.com - March 22 at 4:56 PMSalarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateglobenewswire.com - March 22 at 4:05 PMQuoin stock craters 47% on public offering after rallying in prior sessionmsn.com - March 5 at 2:32 PMQuoin stock soars 60% on FDA update for ichthyosis drugmsn.com - March 4 at 12:43 PMSalarius Pharmaceuticals Implements Cost-savings Measuresmarkets.businessinsider.com - February 22 at 1:52 PMSalarius's CEO David Arthur steps downmsn.com - February 22 at 8:52 AMSalarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expensesfinance.yahoo.com - February 22 at 8:52 AMSalarius Pharmaceuticals Inc (SLRX)uk.investing.com - February 9 at 12:58 AMSalarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degradersfinance.yahoo.com - January 16 at 1:35 PMSquare Pharmaceuticals Ltd.wsj.com - January 13 at 3:02 PMInvestigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollmentfinance.yahoo.com - January 3 at 9:32 AMSLRX Continues Work as it Seeks Alternativesfinance.yahoo.com - November 10 at 4:03 PMSalarius Pharmaceuticals Inc SLRXmorningstar.com - November 8 at 8:37 AMSalarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Programfinance.yahoo.com - November 7 at 10:25 AMSalarius Pharmaceuticals cuts half of workforce despite positive clinical developmentsbizjournals.com - August 10 at 6:57 PMSalarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Updatefinance.yahoo.com - August 10 at 6:57 PMSLRX Pursuing Strategic Alternativesfinance.yahoo.com - August 9 at 3:15 PMSalarius Pharmaceuticals lays off over 50% of staff in search for strategic alternativesendpts.com - August 9 at 10:15 AMWatching Salarius Pharma; Zacks Small-Cap Research Sets $6.75 Price Targetbenzinga.com - July 11 at 5:51 PMSLRX Continues Cancer Fight with Phase I Trial Approvalfinance.yahoo.com - July 11 at 5:51 PMSalarius Pharmaceuticals Gets FDA Clearance for Lymphoma Drug Applicationmarketwatch.com - July 11 at 12:51 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCyclacel PharmaceuticalsNASDAQ:CYCCCyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.LipocineNASDAQ:LPCNLipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1154 for postpartum depression; LPCN 2101 for women with epilepsy; and LPCN 1148, a novel prodrug of testosterone, testosterone laurate for the management of decompensated cirrhosis. It also develops LPCN 1144, an oral prodrug of androgen receptor modulator for the treatment of non-cirrhotic non-alcoholic steatohepatitis, which has completed Phase II testing; LPCN 1111, an oral TRT product of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical testing; and LPCN 1107, an oral hydroxy progesterone caproate product for the prevention of recurrent preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.MYOS RENS TechnologyNASDAQ:MYOSMedAvail Holdings, Inc. is a technology-enabled pharmacy company. It provides turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. The firm helps patients to optimize drug adherence, resulting in better health outcomes. The company is headquartered in Mississauga, Canada.Novelion TherapeuticsOTCMKTS:NVLNFNovelion Therapeutics Inc., a biopharmaceutical company, develops therapies for individuals living with rare diseases in the United States, Japan, Brazil, and internationally. Its commercial products include metreleptin, a recombinant analog of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPTA brand name; and lomitapide capsule for the treatment of adult patients with homozygous familial hypercholesterolemia under the JUXTAPID and LOJUXTA brands. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.Salarius PharmaceuticalsNASDAQ:SLRXSalarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.